Meifeng F. Tu

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.

Journal: BMC medicine

Published: October 10, 2023

Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.

Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.

Journal: Bone marrow transplantation

Published: July 29, 2022

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: November 22, 2021

Primary mediastinal large B cell lymphoma.

Primary mediastinal large B cell lymphoma.

Journal: Thoracic cancer

Published: July 27, 2021

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies.

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies.

Journal: Journal of hematology & oncology

Published: June 01, 2021

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.

Journal: BMC cancer

Published: August 30, 2020

The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients.

The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients.

Journal: Cryobiology

Published: April 10, 2020

Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades.

Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades.

Journal: Cancer medicine

Published: October 26, 2019

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.

Journal: Molecular therapy oncolytics

Published: May 05, 2019

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation.

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: April 19, 2019

Clinical characteristics and survival analysis of de novo grade 3 or transformed follicular lymphoma patients

Clinical characteristics and survival analysis of de novo grade 3 or transformed follicular lymphoma patients

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: October 30, 2018

ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma.

ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma.

Journal: Cancer cell international

Published: October 14, 2018

Showing 1-12 of 43

Last Updated: 09/26/2026